UBS Group
AKBA icon

UBS Group’s Akebia Therapeutics AKBA Stock Holding History

UBS Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.34K Buy
+6,000
New +$8.25K ﹤0.01% 8515

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group's AKBA Position: Q1 2026 in Review

UBS Group reduced its Akebia Therapeutics (AKBA) stake by 12% in Q1 2026, selling an estimated $140K and leaving 769,471 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #5504.

UBS Group first reported a position in AKBA in Q4 2014 and has held it in 46 quarters since. The position peaked at $9.95M in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • UBS Group held 769,471 shares of Akebia Therapeutics worth $1.07M as of Q1 2026.
  • UBS Group sold 102,063 Akebia Therapeutics shares in Q1 2026, an estimated $140K.
  • Akebia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5504 holding.
  • UBS Group first reported a position in Akebia Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Akebia Therapeutics position peaked at $9.95M in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.